New eczema drug candidate enters first human safety trial
NCT ID NCT06553209
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 23 times
Summary
This early-stage study tested a new medicine called CM512 in 110 healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The main goal was to check safety and how the body processes the drug. Researchers gave either a single or multiple doses and compared results to a placebo. This is a first step to see if CM512 might help control eczema symptoms in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Conditions
Explore the condition pages connected to this study.